SRR8518144
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- INTERFERON_ALPHA_RESPONSE+0.520
- MYC_TARGETS_V1+0.470
- E2F_TARGETS+0.400
- INTERFERON_GAMMA_RESPONSE+0.330
- G2M_CHECKPOINT+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.250
- GLYCOLYSIS+0.220
- MTORC1_SIGNALING+0.220
- OXIDATIVE_PHOSPHORYLATION+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- TGF_BETA_SIGNALING-0.410
- ANGIOGENESIS-0.400
- APICAL_JUNCTION-0.360
- HEDGEHOG_SIGNALING-0.350
- UV_RESPONSE_DN-0.320
- ESTROGEN_RESPONSE_EARLY-0.280
- APICAL_SURFACE-0.260
- KRAS_SIGNALING_UP-0.260
- APOPTOSIS-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518323 | — | E | 0.889 |
| 2 | SRR8518141 | — | E | 0.872 |
| 3 | MNG95 | — | — | 0.863 |
| 4 | SRR1516061 | — | — | 0.861 |
| 5 | SRR27320678 | — | — | 0.860 |
| 6 | SRR8613729 | — | E | 0.858 |
| 7 | BS_MMNRZ1EQ | ATRT | — | 0.857 |
| 8 | SRR8518219 | — | E | 0.857 |
| 9 | MNG171 | — | — | 0.853 |
| 10 | GSM6454749 | — | F | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |